Reprint

Model-Informed Precision Dosing

Edited by
March 2023
320 pages
  • ISBN978-3-0365-6896-6 (Hardback)
  • ISBN978-3-0365-6897-3 (PDF)

This is a Reprint of the Special Issue Model-Informed Precision Dosing that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Model-informed precision dosing (MIPD) is an advanced quantitative approach focusing on individualized treatment optimization. MIPD integrates mathematical models of drugs and diseases combined with individual patient characteristics (e.g., genotype, anthropometric factors, and organ function). MIPD has been highlighted as a useful tool for drug dosage selection in both the drug development process and clinical practice and it is a rapidly growing discipline that is supported by the main drug regulatory agencies. Despite the potential benefits of this methodology toward personalized medicine, its application is still limited. The Special Issue presented here includes several PKPD and PBPK models focused on improving the current state of art regarding the PK behaviour of different drugs with the aim of improving the efficacy/safety balance of these treatments and their clinical outcome; the Special Issue is intended to be of particular interest for clinical pharmacologists, pharmacometricians, and specific clinicians who routinely use the considered drugs.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
population pharmacokinetic models; pharmacogenetics; LAI; risperidone; paliperidone; aripiprazole; CYP2D6; antipsychotics; ciprofloxacin; pharmacokinetics; covariates; dosing; NONMEM; renal function; pharmacokinetics; drug monitoring; adalimumab; inflammatory bowel diseases; Crohn’s disease; colitis; ulcerative; infliximab; population pharmacokinetics; inflammatory bowel disease; model-informed precision dosing; dose individualization; ustekinumab; inflammatory bowel disease; fecal calprotectin; pharmacokinetics-pharmacodynamics; therapeutic drug monitoring; infliximab; monoclonal antibody; ulcerative colitis; inflammatory bowel disease; endoscopy; population pharmacokinetics-pharmacodynamics; simulations; therapeutic drug monitoring; model-informed precision dosing; levetiracetam; augmented renal clearance; intensive care; critically ill patients; population pharmacokinetic; modelling; Monte Carlo simulations; seizure; N. gonorrhoeae; antibiotic resistance; cephalosporins; azithromycin; pharmacokinetic/pharmacodynamic (PK/PD) analysis; whole-genome sequencing (WGS); palbociclib; neutropenia; pharmacokinetic/pharmacodynamic; Candida auris; PK/PD model; amphotericin B; time-kill curves; meropenem; population pharmacokinetics; critically ill patient; adult; extracorporeal membrane oxygenation; Monte Carlo simulation; Pseudomonas aeruginosa; pharmacokinetic/pharmacodynamic (PK/PD) analysis; Monte Carlo simulation; antimicrobial resistance; probability of target attainment (PTA); cumulative fraction of response (CFR); model-informed dosing tool; intensive care unit; antibiotic therapy; antimicrobial stewardship; meropenem; pathogen susceptibility; imipenem; population pharmacokinetic modeling; parametric; nonparametric; simulations; donepezil; transdermal patch; equivalent dose optimization; model-based approaches; clinical pharmacokinetics; dosage individualization; Bayesian dosing; therapeutic drug monitoring; Maximum A Posteriori; tuberculosis; population pharmacokinetics; linezolid; auto-inhibition of linezolid elimination; model-informed precision dosing; simulation; drug interactions; therapeutic drug monitoring; epilepsy; NONMEM; population pharmacokinetics; valproic acid; therapeutic drug monitoring; tyrosine kinase inhibitors; cancer; personalized medicine; vancomycin; therapeutic drug monitoring; population pharmacokinetics; precision dosing; predictive performance; model averaging; model selection; Bayesian forecasting; n/a

Related Books